It's January, and I'm sitting across from a pharmacy owner who's been running an independent for eighteen years. Her name is Jennifer. She's scrolling through a price increase list on her screen, and her jaw is getting tighter with each entry.

“Pfizer just raised prices on Nurtec,” she says. “I was buying it just a few weeks ago for less. Now it costs more. My reimbursement? Negative. There’s my margin. Gone.”

She scrolls down. Finds another entry. RSV vaccine. Up 4 percent. Then the shingles vaccine Shingrix. Up 3.5 percent. Then Ibrance, the cancer drug. Up 12 percent.

"This is not new," she says quietly. "But this month, it feels different."

She's right. It does feel different. And here's why.

The 2026 Price Increase Landscape: What You Need to Know

At least 350 branded medications are getting price increases in 2026. The median increase is roughly 4 percent. Some are hitting 12 percent or higher.

Here's what's being raised:

• Pfizer is raising prices on 80 products, including Eliquat (anticoagulation), Prevnar 20 (pneumococcal vaccine), and Xeljanz (immunology).

• Moderna and Pfizer are raising prices on COVID vaccines and RSV vaccine.

• Shingles vaccine (Shingrix, GSK) is up 3.5 percent.

• Ibrance (Pfizer, oncology) is up 12 percent.

The list goes on. And it's happening in a specific context that makes it uniquely dangerous for independent pharmacies.

But here's also important: roughly 9 drugs are getting price CUTS. Boehringer Ingelheim cut Jardiance (diabetes) by 40 percent. A few other manufacturers are following suit. So the market is not uniformly rising. But it's rising enough to hurt.

Why This Moment Feels Different: The Margin Squeeze

Drug price increases are not news to any pharmacy professional. Years of counting pills taught me these cycles have been happening for years. What IS new is the context in which they're happening.

Right now, in 2026, independent pharmacies are facing maximum margin pressure simultaneously.

PBM reimbursement is at historic lows. DIR fees (Direct and Indirect Remuneration) are aggressive and rising. Chain pharmacy competition is fierce. Consolidation is accelerating. Rite Aid is bankrupt. CVS is closing 270 stores. And the patients you depend on are getting more price-sensitive.

Into this environment, a branded manufacturer decides to raise prices on 350 drugs.

Here's the math that Jennifer is doing: her acquisition cost just went up. Her reimbursement did not. Neither did the patient's ability to pay. She absorbed the margin loss.

Multiply this across a thousand NDCs over a year, and you're looking at significant profitability erosion. For a pharmacy operating on 2 to 4 percent margins, this is the difference between sustainability and crisis.

The entrepreneurial response is not to absorb the hit passively. It's to build an active, strategic acquisition cost strategy.

Understanding the Acquisition Cost Equation

Let's get specific about how this actually works, because this is where the solution lives.

When a manufacturer raises the WAC (Wholesale Acquisition Cost) on a drug, several things happen simultaneously:

1. Your primary wholesaler's price goes up.

2. Your reimbursement may or may not adjust, depending on PBM contracts and timing.

3. The gap between your cost and your reimbursement either stays the same, widens, or occasionally narrows.

4. But here's the part most techs don't see: the secondary market price for that medication often moves differently than your primary wholesaler price.

This is important. The secondary market is where pharmacies buy and sell inventory from each other. It includes wholesalers like Cardinal Health's secondary division, independent pharmaceutical distributors, and peer-to-peer pharmacy marketplaces.

When Pfizer raises Eliquat's WAC, your primary wholesaler raises their price. But a pharmacy that overstocked Eliquat before the price increase can sell it at the old market rate.

This is where secondary sourcing becomes not just a nice-to-have, but a survival mechanism.

The Diversified Sourcing Strategy for 2026

Here's how the best-run independents are handling this:

Layer 1: Primary Wholesaler

You still buy most of your volume from your primary wholesaler (Cardinal, McKesson, AmerisourceBergen, local wholesaler). This is your baseline. Don't abandon it. But understand it's only one source.

Layer 2: GPO Membership

GPO (Group Purchasing Organization) membership gives you access to negotiated pricing on volume. If you're not in a GPO, this is the quarter to join. GPOs negotiate contracts with manufacturers and wholesalers, giving you better rates on branded and generic volume.

Layer 3: Direct Manufacturer Contracts

For drugs where you have specialty services (diabetes management, anticoagulation management, oncology support), approach the manufacturer directly. "We are managing 200 diabetic patients. We're providing diabetes counseling and adherence support. What volume discount can you offer us directly?"

Manufacturers love this because it's tied to outcomes and patient engagement. They'll often contract at rates better than your GPO.

Layer 4: Secondary Marketplace

This is the new frontier for independents. Secondary sourcing through peer-to-peer pharmacy marketplaces like RxPost, or through secondary wholesalers.

When another pharmacy has overstocked inventory, they can list it on the secondary market at negotiated rates. You get access to medications at discounts that your primary wholesaler is not offering. The selling pharmacy recovers value from surplus. Everyone wins.

RxPost's data shows that independents are recovering an average of $60,800 in 60 days from surplus inventory. And on sourcing, the average discount versus WAC is 21.8 percent. That's not marginal. That's meaningful margin protection.

Jennifer in my story could have sourced a portion of her Nurtec from a secondary market if she'd had a strategy in place. Different cost basis. Same medication. Different margin.

Practical: The Margin Protection Framework

Here's what to do this month to protect your pharmacy's margins in a rising-price environment.

Step 1: Audit Your Current Sourcing

Pull your acquisition cost data for 20 key medications. This should include:

Your top 20 drugs by volume. The ones you fill daily. The ones that matter to your margin.

Document the cost from your primary wholesaler. Document the reimbursement you're getting from major PBMs. Calculate the gross margin on each.

This is your baseline. This is what you're protecting.

Step 2: Identify Price Increase Exposure

Cross-reference your top 20 with the list of drugs getting 2026 price increases. Which ones are you filling regularly that are on the increase list?

Pfizer's 80 products. The vaccines. Jardiance (before the cut). Ibrance. Are you dispensing these?

Calculate the impact if the price increases hit and your reimbursement doesn't adjust. What's the margin impact?

Step 3: Map Your Alternative Sources

For the drugs you identified as exposure:

Are you in a GPO? Call them. Ask if they have better pricing on these specific drugs post-increase. If not, why? Is this GPO worth keeping?

Research one manufacturer contract. Pick one diabetes drug or one specialty drug your pharmacy is known for. Reach out to the sales rep. "We have an opportunity to deepen this therapy's use in our community. What volume commitment would it take to access a better price?"

Identify the secondary marketplace option that fits your workflow. RxPost. Others. Look at their pricing for the drugs you identified. Get real data.

Step 4: Create a Sourcing Decision Tree

For each drug you identified as exposure:

If acquisition cost from primary wholesaler is above reimbursement, what's your fallback?

Primary wholesaler first? Yes. But if primary is not workable, secondary source becomes your option.

Build this decision-making into your workflow. Make it part of your ordering process. Not after you've already lost margin, but before.

The 9 Drugs Getting Cheaper: Don't Sleep on This

While we're focused on the 350 drugs going up, I want to flag something important. About 10 drugs are getting significant price cuts, and the most notable is Jardiance down 40 percent.

This is Boehringer Ingelheim's direct response to biosimilar pressure and insurance formulary changes. The point: price doesn't move in one direction. Sometimes it swings hard the other way.

This is actually an opportunity if you've been holding inventory. If you're smart about acquisition cost, you can be aggressive on volume for Jardiance right now, knowing your future cost basis will be better.

This is where entrepreneurial thinking beats passive margin management.

The Bigger Truth About Margins and Survival

Here's what Jennifer understood sitting in her office scrolling through price increases. Pharmacy margins have been hollowed out by PBM reimbursement practices. That's not news. But it's background radiation to everything you do now.

You cannot restore margins by hoping reimbursement improves. You cannot restore margins by turning patient volume. You have to restore them by being smart about acquisition cost.

That means diversifying your sourcing. Building relationships with multiple wholesalers. Using secondary markets strategically. Negotiating directly when you can. Making micro-adjustments across hundreds of NDCs.

This is not heroic work. It's steady, methodical, operational excellence. And it's the difference between a pharmacy that survives 2026 and one that doesn't.

Jennifer is doing this work now. She's mapped her exposure, built her sourcing strategy, and is training her team on the new decision rules. When Pfizer's next price increase hits, she'll have options. That's protection.

Take Action This Week

If you're in an independent pharmacy:

1. Pull acquisition cost data for your top 20 drugs. This week. Not next week.

2. Cross-reference against the 2026 price increase list. Which are you exposed to?

3. Call your GPO and ask specifically about pricing on the drugs where you have margin exposure. If they can't help, that's information.

4. Research one secondary marketplace. Get pricing data for 3 of your exposed drugs. See the gap between primary and secondary costs.

If you're leading a pharmacy team:

Have one conversation with your pharmacy operations lead or owner about acquisition cost strategy. Not a vague conversation about "reducing costs." A specific one: "How are we going to handle the drug price increases happening right now? What's our sourcing strategy?"